Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma

Luca Castagna; Barbara Sarina; Elisabetta Todisco; Massimo Magagnoli; Monica Balzarotti; Stefania Bramanti; Rita Mazza; Antonella Anastasia; Andrea Bacigalupo; Franco Aversa; Davide Soligo; Laura Giordano; Armando Santoro

doi:10.1016/j.bbmt.2008.12.506

Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma

Luca Castagna, Barbara Sarina, Elisabetta Todisco, Massimo Magagnoli, Monica Balzarotti, Stefania Bramanti, Rita Mazza, Antonella Anastasia, Andrea Bacigalupo, Franco Aversa, Davide Soligo, Laura Giordano, Armando Santoro

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.

Original language	English
Pages (from-to)	432-438
Number of pages	7
Journal	Biology of Blood and Marrow Transplantation
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.bbmt.2008.12.506
Publication status	Published - Apr 2009

Keywords

Allogeneic transplantation
High-dose chemotherapy
Hodgkin lymphoma
Salvage chemotherapy

ASJC Scopus subject areas

Transplantation
Hematology

Access to Document

10.1016/j.bbmt.2008.12.506

Cite this

Castagna, L., Sarina, B., Todisco, E., Magagnoli, M., Balzarotti, M., Bramanti, S., Mazza, R., Anastasia, A., Bacigalupo, A., Aversa, F., Soligo, D., Giordano, L., & Santoro, A. (2009). Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 15(4), 432-438. https://doi.org/10.1016/j.bbmt.2008.12.506

Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma. / Castagna, Luca ; Sarina, Barbara ; Todisco, Elisabetta; Magagnoli, Massimo; Balzarotti, Monica ; Bramanti, Stefania ; Mazza, Rita; Anastasia, Antonella; Bacigalupo, Andrea; Aversa, Franco; Soligo, Davide; Giordano, Laura ; Santoro, Armando.

In: Biology of Blood and Marrow Transplantation, Vol. 15, No. 4, 04.2009, p. 432-438.

Research output: Contribution to journal › Article › peer-review

Castagna, L , Sarina, B , Todisco, E, Magagnoli, M, Balzarotti, M , Bramanti, S , Mazza, R, Anastasia, A, Bacigalupo, A, Aversa, F, Soligo, D, Giordano, L & Santoro, A 2009, 'Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma', Biology of Blood and Marrow Transplantation, vol. 15, no. 4, pp. 432-438. https://doi.org/10.1016/j.bbmt.2008.12.506

Castagna, Luca ; Sarina, Barbara ; Todisco, Elisabetta ; Magagnoli, Massimo ; Balzarotti, Monica ; Bramanti, Stefania ; Mazza, Rita ; Anastasia, Antonella ; Bacigalupo, Andrea ; Aversa, Franco ; Soligo, Davide ; Giordano, Laura ; Santoro, Armando. / Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma. In: Biology of Blood and Marrow Transplantation. 2009 ; Vol. 15, No. 4. pp. 432-438.

@article{fa192e10fe704e8780175c8458afcf61,

title = "Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma",

abstract = "The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.",

keywords = "Allogeneic transplantation, High-dose chemotherapy, Hodgkin lymphoma, Salvage chemotherapy",

author = "Luca Castagna and Barbara Sarina and Elisabetta Todisco and Massimo Magagnoli and Monica Balzarotti and Stefania Bramanti and Rita Mazza and Antonella Anastasia and Andrea Bacigalupo and Franco Aversa and Davide Soligo and Laura Giordano and Armando Santoro",

year = "2009",

month = apr,

doi = "10.1016/j.bbmt.2008.12.506",

language = "English",

volume = "15",

pages = "432--438",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma

AU - Castagna, Luca

AU - Sarina, Barbara

AU - Todisco, Elisabetta

AU - Magagnoli, Massimo

AU - Balzarotti, Monica

AU - Bramanti, Stefania

AU - Mazza, Rita

AU - Anastasia, Antonella

AU - Bacigalupo, Andrea

AU - Aversa, Franco

AU - Soligo, Davide

AU - Giordano, Laura

AU - Santoro, Armando

PY - 2009/4

Y1 - 2009/4

N2 - The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.

AB - The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.

KW - Allogeneic transplantation

KW - High-dose chemotherapy

KW - Hodgkin lymphoma

KW - Salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=61749102653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749102653&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.12.506

DO - 10.1016/j.bbmt.2008.12.506

M3 - Article

C2 - 19285630

AN - SCOPUS:61749102653

VL - 15

SP - 432

EP - 438

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -

Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this